Key result
Impella 5.5 in cardiogenic shock linked to >2000 mL/day urine output, allowing CRRT discontinuation.
Why the study?
Does Impella 5.5 improve persistent anuria in a patient with severe myocardial infarction and cardiogenic shock?
Case Report (n=1)
No
Does Impella 5.5 improve persistent anuria in a patient with severe myocardial infarction and cardiogenic shock?
Impella 5.5 may serve as an effective bridge to decision by improving end-organ perfusion and reversing anuria in patients with severe cardiogenic shock.
May support Impella 5.5 for renal recovery in cardiogenic shock anuria; hypothesis-generating and requires prospective validation.
A man in his 40s with ST-segment elevation myocardial infarction complicating cardiogenic shock was transferred to our hospital. Emergent percutaneous coronary intervention for the left anterior descending and left circumflex arteries supported with Impella CP was performed. However, his cardiac function was severely impaired, and anuria developed, necessitating continuous renal replacement therapy (CRRT). After Impella CP was removed on day 6, the patient remained dependent on inotropes and CRRT. Following volume reduction to manage pulmonary congestion, symptoms of low perfusion appeared. Then, Impella 5.5 was inserted on day 38 as a bridge to decision. On day 52, the urine volume reached >2000 mL/day, and CRRT was discontinued. On day 56, the patient was transferred to a certified facility for left ventricular assist device implantation or heart transplantation. This case suggests the potential of Impella 5.5 as a bridge to decision in patients with organ failure caused by low cardiac output.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2023) conducted a case report in ST-segment elevation myocardial infarction complicating cardiogenic shock (n=1). Impella 5.5 was evaluated on Urine volume and discontinuation of continuous renal replacement therapy. Insertion of Impella 5.5 as a bridge to decision in a patient with cardiogenic shock and anuria improved urine volume to >2000 mL/day, allowing discontinuation of renal replacement therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: